Jose Marques Lopes, PhD,  —

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

Articles by Jose Marques Lopes

Reata’s Bardoxolone for Alport Syndrome Granted FDA Orphan Drug Status

Bardoxolone methyl, an investigational treatment for kidney damage associated with Alport syndrome, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA), Reata Pharmaceuticals announced. Bardoxolone methyl (bardoxolone) is an oral, once-daily therapy that is being evaluated in the CARDINAL Phase 2/3 clinical trial (NCT03019185) in patients with chronic kidney disease…

Create your own user feedback survey